In this study, EZH2 inhibitors not only exerted anti-tumor effects as epigenetic agents, but also enhanced the anti-tumor effects of TIGIT monoclonal antibodies by affecting the TIGIT-CD155 axis between NK cells and MM cells, providing new ideas and preliminary theoretical basis for the treatment of MM patients. Here, TIGIT is linked to Miyoshi myopathy.